Skip to main content
. Author manuscript; available in PMC: 2015 May 15.
Published in final edited form as: J Immunol. 2014 Apr 9;192(10):4795–4803. doi: 10.4049/jimmunol.1302764

Figure 6. Co-administration of human resistin and LPS increases the severity of ALI.

Figure 6

(A, B, C, and D) wild type mice were subjected to intratracheal (i.t.) instillation of purified human resistin (0.5 mg/kg), LPS (2 mg/kg), or combined administration of human resistin and LPS, and then BALs obtained 24 hours later. Panels (A ) and (B) show numbers of total white cells, neutrophils and levels of TNF-α and MIP-2 in BAL fluid (Means ± SD, n = 4, * P < 0.05; ** P < 0.01). (D) Representative Western blots showing phospho-Ser172 AMPK, total AMPK, and β-actin in lung homogenates. (E and F) hRTN+/−/− mice were treated with saline or AICAR (i.p., 500 mg/kg) 4 hours prior to intratracheal instillation of LPS (2 mg/kg). Numbers of neutrophils (E) and levels of TNF-α (F) in BAL fluids were measured 24 hours after LPS injection (Means ± SD, n = 4, * P < 0.05).